Investigation of interaction between human hemoglobin A0 and platinum anticancer drugs by capillary isoelectric focusing with whole column imaging detection.
CIEF with whole column imaging detection (WCID) was used to investigate the interaction of platinum-based anticancer drugs, cis-platinum(II) diamine dichloride (cisplatin) and [SP-4-2-{1R-trans)]-(1,2-cyclohexanediamine-N,N')[ethanedioata(2-)-O,O']platinum (oxaliplatin), with human hemoglobin A(0) (Hb). This technique facilitates the investigation and characterization of the formation of adducts between drugs and proteins. Cisplatin and oxaliplatin were mixed with the target protein at different concentrations (0:1, 1:1, 1:10, 1:50, and 1:100), and the reaction mixtures were incubated for 0, 0.5, 1, 12, 24, 48, and 72 h at 37 degrees C in a water-bath. The focused Hb-drug adduct profiles were imaged by WCID. At higher drug to protein molar ratios (for both oxaliplatin and cisplatin), the results exhibit significant changes in the peak shapes and heights, which may indicate the destabilization of the protein. However, the conformational change was less evident at lower molar ratios. In addition, a major pI shift was observed for the oxaliplatin reaction mixtures (for 1:10, 1:50, and 1:100 ratios). In comparison with previously reported findings obtained by other analytical methods, conclusions were drawn about the validity of CIEF as a simple and convenient method for the investigation of protein-drug interactions. These results may provide useful information for further understanding the activity and toxicity of these chemotherapeutic drugs and improving their clinical performance.
Lemma
Tibebe
T
Department of Chemistry, University of Waterloo, Waterloo, Ontario, Canada.
Mandal
Rupasri
R
Li
Xing-Fang
XF
Pawliszyn
Janusz
J
D000970:Antineoplastic Agents / Q000032:analysis* / Q000737:chemistry; D002623:Chemistry Techniques, Analytical / Q000379:methods*; D002945:Cisplatin / Q000032:analysis*; D019075:Electrophoresis, Capillary; D006441:Hemoglobin A / Q000032:analysis*; D006801:Humans; D007525:Isoelectric Focusing / Q000379:methods*; D007526:Isoelectric Point; D008968:Molecular Conformation; D009944:Organoplatinum Compounds / Q000032:analysis*; D000077150:Oxaliplatin; D011485:Protein Binding; D013696:Temperature; D013997:Time Factors
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D006441:Hemoglobin A; D002945:Cisplatin